{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:12:29Z","timestamp":1769127149348,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00467-018-4006-3","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T04:41:25Z","timestamp":1531111285000},"page":"2095-2101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?"],"prefix":"10.1007","volume":"33","author":[{"given":"Juan","family":"Politei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Alberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Amoreo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norberto","family":"Antongiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Nieves","family":"Ar\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Bar\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Di Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Fainboim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Frabasil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Gomez","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Iotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Liern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Perretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ripeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Toniolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernan","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana Velasques","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Beatriz","family":"Schenone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"key":"4006_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123:416\u2013427","journal-title":"Mol Genet Metab"},{"key":"4006_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30\u201378","journal-title":"Orphanet J Rare Dis"},{"key":"4006_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89:44\u201354","journal-title":"Clin Genet"},{"key":"4006_CR4","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105:2812\u20132817","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4006_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","volume":"152","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, Germain DP (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152:563\u2013570","journal-title":"J Pediatr"},{"key":"4006_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","volume":"83","author":"L Borgwardt","year":"2013","unstructured":"Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard Lund A (2013) Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet 83:432\u2013438","journal-title":"Clin Genet"},{"key":"4006_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1542\/peds.2005-2895","volume":"118","author":"M Ries","year":"2006","unstructured":"Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924\u2013932","journal-title":"Pediatrics"},{"key":"4006_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","volume":"29","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, Paulero M, Rengel T, Ar\u00e1oz A, Forrester M, Lombi F, Pomeranz V, Iriarte R, Young P, Muryan A, Zotta E (2016) Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. J Nephrol 29:791\u2013797","journal-title":"J Nephrol"},{"key":"4006_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C T\u00f8ndel","year":"2008","unstructured":"T\u00f8ndel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767\u2013776","journal-title":"Am J Kidney Dis"},{"key":"4006_CR10","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","volume":"25","author":"AB Fogo","year":"2010","unstructured":"Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, Howie AJ, Burns A, Reeve R, Waldek S, No\u00ebl LH, Gr\u00fcnfeld JP, Valbuena C, Oliveira JP, M\u00fcller J, Breunig F, Zhang X, Warnock DG (2010) Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 25:2168\u20132177","journal-title":"Nephrol Dial Transplant"},{"key":"4006_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550\u2013555","journal-title":"Pediatr Res"},{"key":"4006_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/gim.2014.120","volume":"17","author":"DA Laney","year":"2015","unstructured":"Laney DA, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, Grange DK, Wilcox WR, Hopkin RJ (2015) Fabry disease in infancy and early childhood: a systematic literature review. Genet Med 17:323\u2013330","journal-title":"Genet Med"},{"key":"4006_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12886-016-0374-2","volume":"16","author":"G Kalkum","year":"2016","unstructured":"Kalkum G, Pitz S, Karabul N, Beck M, Pintos-Morell G, Parini R, Rohrbach M, Bizjajeva S, Ramaswami U (2016) Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC Ophthalmol 16:202\u2013208","journal-title":"BMC Ophthalmol"},{"key":"4006_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C, Participants C (2017) Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference. Kidney Int 91:284\u2013293","journal-title":"Kidney Int"},{"key":"4006_CR15","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2008.02.050","volume":"51","author":"GE Linthorst","year":"2008","unstructured":"Linthorst GE, Poorthuis BJ, Hollak CE (2008) Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol 51:2082","journal-title":"J Am Coll Cardiol"},{"key":"4006_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","volume":"353","author":"GE Linthorst","year":"2005","unstructured":"Linthorst GE, Vedder AC, Aerts JM, Hollak CE (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201\u2013203","journal-title":"Clin Chim Acta"},{"key":"4006_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","volume":"52","author":"BE Smid","year":"2015","unstructured":"Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ (2015) Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet 52:262\u2013268","journal-title":"J Med Genet"},{"key":"4006_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F (2014) Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet 7:8\u201316","journal-title":"Circ Cardiovasc Genet"},{"key":"4006_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/humu.22910","volume":"37","author":"J Lukas","year":"2016","unstructured":"Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, Giese AK, Rolfs A (2016) Functional and clinical consequences of novel \u03b1-galactosidase a mutations in Fabry disease. Hum Mutat 37:43\u201351","journal-title":"Hum Mutat"},{"key":"4006_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13052-016-0320-1","volume":"43","author":"M Spada","year":"2017","unstructured":"Spada M, Kasper D, Pagliardini V, Biamino E, Giachero S, Porta F (2017) Metabolic progression to clinical phenotype in classic Fabry disease. Ital J Pediatr 43:1\u20133","journal-title":"Ital J Pediatr"},{"key":"4006_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC (2017) Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab 120:57\u201361","journal-title":"Mol Genet Metab"},{"key":"4006_CR22","doi-asserted-by":"publisher","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","volume":"10","author":"FA Wijburg","year":"2015","unstructured":"Wijburg FA, B\u00e9nichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini C, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, T\u00f8ndel C, Tylki-Szyma\u0144ska A, Ramaswami U (2015) Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS One 10:e0124987","journal-title":"PLoS One"},{"key":"4006_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC (2018) Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab 123:148\u2013153","journal-title":"Mol Genet Metab"},{"key":"4006_CR24","first-page":"257628","volume":"2015","author":"H Trimarchi","year":"2015","unstructured":"Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Forrester M, Karl A, Lombi F, Andrews J, Pomeranz V, Rengel T, Zotta E (2015) Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease. Case Rep Nephrol 2015:257628","journal-title":"Case Rep Nephrol"},{"key":"4006_CR25","doi-asserted-by":"publisher","first-page":"e0168346","DOI":"10.1371\/journal.pone.0168346","volume":"11","author":"B Fall","year":"2016","unstructured":"Fall B, Scott CR, Mauer M, Shankland S, Pippin J, Jefferson JA, Wallace E, Warnock D, Najafian B (2016) Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical severity of Fabry nephropathy. PLoS One 11:e0168346","journal-title":"PLoS One"},{"key":"4006_CR26","first-page":"49","volume":"38","author":"EM Pereira","year":"2016","unstructured":"Pereira EM, Silva AS, Labilloy A, Monte Neto JT, Monte SJ (2016) Podocyturia in Fabry disease. J Bras Nefrol 38:49\u201353","journal-title":"J Bras Nefrol"},{"key":"4006_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ki.2010.484","volume":"79","author":"B Najafian","year":"2011","unstructured":"Najafian B, Svarstad E, Bostad L, Gubler MC, T\u00f8ndel C, Whitley C, Mauer M (2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 79:663\u2013670","journal-title":"Kidney Int"},{"key":"4006_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00467-012-2222-9","volume":"28","author":"B Najafian","year":"2013","unstructured":"Najafian B, Mauer M, Hopkin RJ, Svarstad E (2013) Renal complications of Fabry disease in children. Pediatr Nephrol 28:679\u2013687","journal-title":"Pediatr Nephrol"},{"key":"4006_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000369309","volume":"129","author":"C T\u00f8ndel","year":"2015","unstructured":"T\u00f8ndel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG, Svarstad E (2015) Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron 129:16\u201321","journal-title":"Nephron"},{"key":"4006_CR30","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1053\/j.ajkd.2015.08.006","volume":"66","author":"B Najafian","year":"2015","unstructured":"Najafian B, Fogo AB, Lusco MA, Alpers CE (2015) AJKD atlas of renal pathology: Fabry nephropathy. Am J Kidney Dis 66:e35\u2013e36","journal-title":"Am J Kidney Dis"},{"key":"4006_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.08091109","volume":"5","author":"U Ramaswami","year":"2010","unstructured":"Ramaswami U, Najafian B, Schieppati A, Mauer M, Bichet DG (2010) Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol 5:365\u2013370","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"4006_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000327075","volume":"33","author":"B Najafian","year":"2011","unstructured":"Najafian B, Mauer M (2011) Quantitating glomerular endothelial fenestration: an unbiased stereological approach. Am J Nephrol 33(Suppl 1):34\u201339","journal-title":"Am J Nephrol"},{"key":"4006_CR33","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2215\/CJN.01820217","volume":"12","author":"R Skrunes","year":"2017","unstructured":"Skrunes R, T\u00f8ndel C, Leh S, Larsen KK, Houge G, Davidsen ES, Hollak C, van Kuilenburg ABP, Vaz FM, Svarstad E (2017) Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease. Clin J Am Soc Nephrol 12:1470\u20131479","journal-title":"Clin J Am Soc Nephrol"},{"key":"4006_CR34","first-page":"807","volume":"32","author":"R Skrunes","year":"2017","unstructured":"Skrunes R, Svarstad E, Kampevold Larsen K, Leh S, T\u00f8ndel C (2017) Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrol Dial Transplant 32:807\u2013813","journal-title":"Nephrol Dial Transplant"},{"key":"4006_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137\u2013148","journal-title":"J Am Soc Nephrol"},{"key":"4006_CR36","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00467-016-3387-4","volume":"31","author":"S Ito","year":"2016","unstructured":"Ito S, Ogura M, Kamei K, Matsuoka K, Warnock DG (2016) Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta. Pediatr Nephrol 31:1369\u20131373","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4006-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T19:12:30Z","timestamp":1562613150000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4006-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4006"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4006-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"13 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Juan Politei received honoraria for lectures on Fabry disease from Sanofi Genzyme, Shire HGT, Amicus, Actelion, and Protalix. Consuelo Durand, Alejandro Fainboim, Andrea Beatriz Schenone received honoraria for lectures from Sanofi Genzyme and Biomarin. Hernan Trimarchi received honoraria for lectures on Fabry disease from Sanofi Genzyme. The other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Authors have no financial relationships relevant to this article to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"All parents signed a written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}